9220.T
The company operates in the healthcare sector, providing biotechnology services and equipment, and generates revenue primarily through its operations in healthcare facilities and services.
Business. The company operates in the healthcare sector, providing biotechnology services and equipment, and generates revenue primarily through its operations in healthcare facilities and services.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the healthcare sector, providing biotechnology services and equipment, and generates revenue primarily through its operations in healthcare facilities and services.
The company maintains a debt-to-equity ratio of 0.99, indicating a balanced capital structure with a moderate level of leverage. Its liquidity position is characterized by a current ratio of 1.58, suggesting the company has sufficient short-term assets to cover its short-term liabilities. However, the company's net cash position is negative after subtracting total debt, which may pose a liquidity risk.
In terms of profitability, the company's return on equity (ROE) is 11.16%, and its return on assets (ROA) is 4.59%. These figures are below the industry median for ROE and ROA, indicating that the company is underperforming its peers in terms of generating returns on equity and assets.
The company's revenue is concentrated in a single business segment, with no significant geographic diversification reported. This concentration may increase the company's exposure to market-specific risks, as the performance of the company is closely tied to the success of its primary business segment.
The company's growth trajectory is modest, with no significant revenue growth reported in the most recent fiscal year. The company's capital expenditure is negative, indicating a reduction in investment in long-term assets. This may suggest a conservative approach to capital spending or a focus on cost optimization.
The company's risk profile is characterized by a medium liquidity risk and a low dilution risk. The negative net cash position after subtracting total debt is a key flag, indicating potential liquidity constraints. The company has not made any recent equity issuances or share buybacks that would significantly impact its capital structure.
Recent events, including financial filings and transcripts, do not indicate any material changes in the company's operations or strategic direction. The company's financial performance remains stable, with no significant disruptions reported in the most recent filings.
- The company has a balanced capital structure with a debt-to-equity ratio of 0.99.
- The company's return on equity and return on assets are below the industry median, indicating underperformance.
- The company's revenue is concentrated in a single business segment, increasing its exposure to market-specific risks.
- The company's growth trajectory is modest, with no significant revenue growth reported in the most recent fiscal year.
- The company's liquidity risk is medium, and its dilution risk is low.
- "margin_outlook_rationale": "The company's gross profit margin is expected to remain stable, driven by consistent cost management and pricing strategies.",
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 9220.T Market data — financials · 2026-05-27
- FB Care Service Co Ltd Market data — analyst estimates · 2026-05-27